For decades, studies on Gerson therapy for cancer have questioned its safety and efficacy. But, what does the latest head-to-head trial of a Gerson-style regime, versus chemotherapy, show in terms of survival and quality of life for pancreatic cancer ?
Gerson-style Therapy vs. Chemotherapy
Below is an approximation of this video’s audio content. To see any graphs, charts, graphics, images, and quotes to which Dr. Greger may be referring, watch the above video.
The recent review dismissing Gerson therapy as useless or worse for the treatment of cancer was published before this landmark study came out: a head-to-head test of a Gerson-style regime, versus the standard chemotherapy agent gemcitabine, for pancreatic cancer—one of the deadliest of all malignancies.
Being diagnosed with inoperable pancreatic cancer is, basically, on average, being given a six-month death sentence. The best modern medicine can offer is chemotherapy designed not to cure, but just to kind of slow down the death process, and give people a few extra months. Since death is essentially considered inevitable, it offers an opportunity to try untested therapies—because what’s the worst that can happen?
Now, you’d think with all the interest in complementary and alternative medicine, there’d be lots of these trials. But, they’re actually exceedingly rare, and difficult to do. The National Cancer Institute and American Cancer Society should be commended for their efforts here.
So, 55 patients; 23 chose chemo; 32 chose treatment with enzyme supplements, detox, and an organic diet, composed mostly of raw foods.
This may be among the “first controlled, clinical studies to compare allopathic [meaning standard medical] treatment to an alternative medicine program for a survival end point.” What did they find?
Well, first of all, before they even started, they agreed on what’s called a “stopping rule.” If one therapy started working way better than the other, then they’d just stop it [the study], because it would be unethical to continue. That point was reached, actually, and they had to stop the study prematurely because there were so many more deaths—in the Gerson therapy alternative group.
Here’s the survival curve. Here’s the chemo group. As you can see, despite conventional medicine’s best efforts, about half were dead in a year. But, here’s the enzyme and raw food group. As you can see, they started dying off almost immediately, whereas those in the chemo group tended to be able to hold out longer.
Yeah, but what about the quality of their lives in their last few months on earth? Quality of life was significantly better in the chemo group, as well.
“Conclusion: Among patients who have pancreatic cancer, those who chose gemcitabine-based chemotherapy survived more than three times as long [14 months, on average, versus 4 months]…and had better quality of life than those who chose [the alternative] proteolytic enzyme treatment.”
Please consider volunteering to help out on the site.
- Chabot JA, Tsai WY, Fine RL, Chen C, Kumah CK, Antman KA, Grann VR. Pancreatic proteolytic enzyme therapy compared with gemcitabine-based chemotherapy for the treatment of pancreatic cancer. J Clin Oncol. 2010 Apr 20;28(12):2058-63.
- Cassileth B. Gerson regimen. Oncology (Williston Park). 2010 Feb;24(2):201.
Images thanks to Ben Stanfield and Jason Eppink via flickr; and National Cancer Institute/NIH
Below is an approximation of this video’s audio content. To see any graphs, charts, graphics, images, and quotes to which Dr. Greger may be referring, watch the above video.
The recent review dismissing Gerson therapy as useless or worse for the treatment of cancer was published before this landmark study came out: a head-to-head test of a Gerson-style regime, versus the standard chemotherapy agent gemcitabine, for pancreatic cancer—one of the deadliest of all malignancies.
Being diagnosed with inoperable pancreatic cancer is, basically, on average, being given a six-month death sentence. The best modern medicine can offer is chemotherapy designed not to cure, but just to kind of slow down the death process, and give people a few extra months. Since death is essentially considered inevitable, it offers an opportunity to try untested therapies—because what’s the worst that can happen?
Now, you’d think with all the interest in complementary and alternative medicine, there’d be lots of these trials. But, they’re actually exceedingly rare, and difficult to do. The National Cancer Institute and American Cancer Society should be commended for their efforts here.
So, 55 patients; 23 chose chemo; 32 chose treatment with enzyme supplements, detox, and an organic diet, composed mostly of raw foods.
This may be among the “first controlled, clinical studies to compare allopathic [meaning standard medical] treatment to an alternative medicine program for a survival end point.” What did they find?
Well, first of all, before they even started, they agreed on what’s called a “stopping rule.” If one therapy started working way better than the other, then they’d just stop it [the study], because it would be unethical to continue. That point was reached, actually, and they had to stop the study prematurely because there were so many more deaths—in the Gerson therapy alternative group.
Here’s the survival curve. Here’s the chemo group. As you can see, despite conventional medicine’s best efforts, about half were dead in a year. But, here’s the enzyme and raw food group. As you can see, they started dying off almost immediately, whereas those in the chemo group tended to be able to hold out longer.
Yeah, but what about the quality of their lives in their last few months on earth? Quality of life was significantly better in the chemo group, as well.
“Conclusion: Among patients who have pancreatic cancer, those who chose gemcitabine-based chemotherapy survived more than three times as long [14 months, on average, versus 4 months]…and had better quality of life than those who chose [the alternative] proteolytic enzyme treatment.”
Please consider volunteering to help out on the site.
- Chabot JA, Tsai WY, Fine RL, Chen C, Kumah CK, Antman KA, Grann VR. Pancreatic proteolytic enzyme therapy compared with gemcitabine-based chemotherapy for the treatment of pancreatic cancer. J Clin Oncol. 2010 Apr 20;28(12):2058-63.
- Cassileth B. Gerson regimen. Oncology (Williston Park). 2010 Feb;24(2):201.
Images thanks to Ben Stanfield and Jason Eppink via flickr; and National Cancer Institute/NIH
Republishing "Gerson-style Therapy vs. Chemotherapy"
You may republish this material online or in print under our Creative Commons licence. You must attribute the article to NutritionFacts.org with a link back to our website in your republication.
If any changes are made to the original text or video, you must indicate, reasonably, what has changed about the article or video.
You may not use our material for commercial purposes.
You may not apply legal terms or technological measures that restrict others from doing anything permitted here.
If you have any questions, please Contact Us
Gerson-style Therapy vs. Chemotherapy
LicenseCreative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)
Content URLDoctor's Note
For an introduction to Gerson Therapy, check out my “prequel” video, Gerson Therapy for Cancer. Dietary strategies associated with prolonged longevity after diagnosis (also see my dozens of other videos on cancer survival) can be found in Breast Cancer Survival and Soy; Breast Cancer Survival and Lignan Intake; Raw Broccoli and Bladder Cancer Survival; and Slowing the Growth of Cancer.
For further context, check out my associated blog post: Gerson Therapy for Cancer?
If you haven't yet, you can subscribe to our free newsletter. With your subscription, you'll also get notifications for just-released blogs and videos. Check out our information page about our translated resources.